Insights

Innovative Genomics Focus Genos is leveraging next-generation sequencing technology to compete with major industry players like Illumina and 23andMe, indicating a strong foundation for cutting-edge genetic analysis services suitable for collaboration or licensing agreements.

Strong Funding Backing With a strategic investment of $6 million from NantOmics, Genos demonstrates financial backing that supports scaling research capabilities and expanding product offerings, creating opportunities for partnerships in biotech development.

Emphasis on Data Ownership Genos's core mission revolves around individual control of genetic data, opening avenues for personalized health solutions, data privacy platforms, and secure data management services tailored to consumer needs.

Market Positioning Positioned as a competitor to established consumer genomics firms like 23andMe and Ancestory.com, Genos presents opportunities to develop differentiated services, particularly in health-focused genomic applications and user-centric research collaborations.

Emerging Market Potential Despite current revenues below one million dollars, Genos's innovative approach and recent investments suggest significant growth potential in personalized medicine, genomic research collaborations, and health diagnostics markets.

Similar companies to Genos (acquired by NantOmics)

Genos (acquired by NantOmics) Tech Stack

Genos (acquired by NantOmics) uses 8 technology products and services including Facebook Pixel, Amazon CloudFront, Google Workspace, and more. Explore Genos (acquired by NantOmics)'s tech stack below.

  • Facebook Pixel
    Analytics
  • Amazon CloudFront
    Content Delivery Network
  • Google Workspace
    Email
  • Google Fonts API
    Font Scripts
  • Moment.js
    Javascript Libraries
  • Underscore.js
    Javascript Libraries
  • Bootstrap
    UI Frameworks
  • Facebook
    Widgets

Genos (acquired by NantOmics)'s Email Address Formats

Genos (acquired by NantOmics) uses at least 2 format(s):
Genos (acquired by NantOmics) Email FormatsExamplePercentage
First.Last@nantomics.comJohn.Doe@nantomics.com
83%
Last@nantomics.comDoe@nantomics.com
13%
FLast@nantomics.comJDoe@nantomics.com
4%

Frequently Asked Questions

What is Genos (acquired by NantOmics)'s official website and social media links?

Minus sign iconPlus sign icon
Genos (acquired by NantOmics)'s official website is genos.co and has social profiles on LinkedIn.

What is Genos (acquired by NantOmics)'s SIC code NAICS code?

Minus sign iconPlus sign icon
Genos (acquired by NantOmics)'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Genos (acquired by NantOmics) have currently?

Minus sign iconPlus sign icon
As of December 2025, Genos (acquired by NantOmics) has approximately 11 employees across 1 continents, including North America. Key team members include Proteomics Laboratory Medical Director: R. H.. Explore Genos (acquired by NantOmics)'s employee directory with LeadIQ.

What industry does Genos (acquired by NantOmics) belong to?

Minus sign iconPlus sign icon
Genos (acquired by NantOmics) operates in the Biotechnology Research industry.

What technology does Genos (acquired by NantOmics) use?

Minus sign iconPlus sign icon
Genos (acquired by NantOmics)'s tech stack includes Facebook PixelAmazon CloudFrontGoogle WorkspaceGoogle Fonts APIMoment.jsUnderscore.jsBootstrapFacebook.

What is Genos (acquired by NantOmics)'s email format?

Minus sign iconPlus sign icon
Genos (acquired by NantOmics)'s email format typically follows the pattern of First.Last@nantomics.com. Find more Genos (acquired by NantOmics) email formats with LeadIQ.

When was Genos (acquired by NantOmics) founded?

Minus sign iconPlus sign icon
Genos (acquired by NantOmics) was founded in 2016.

Genos (acquired by NantOmics)

Biotechnology ResearchCalifornia, United States11-50 Employees

We’ve built Genos to change the status quo of health and wellness discovery, ground up. And we believe doing so should not come at the cost of separating people from what inherently belongs to them – their genetic data.

Genos is anchored by the principle of individual ownership. We are setting the foundation for a world where you are always in control – to own your data, know your data and employ your DNA for your value or for shared value. Our commitment is to temper the institutional control and ‘profiting’ of your DNA, which harms scientific progress and violates your right to deliberate choice and a fair market.

The future is collectively ours, but it’s shaped by individuals who help move the world by paying it forward through advocacy and action. We are building a community that transparently and securely brings together research and service partners required to create the change we need to further health discovery – and you sit at the center. With your help, we can learn about the genetic heritage that we share and also makes us each unique. We can support scientific discovery to understand, prevent and cure diseases that impact all of us.

Avenues of action are imperative to further science, and our mission is to provide them, fairly. It’s time to be afforded the right paths to own your sequence, take action, and explore freely.

On your terms.

Section iconCompany Overview

Website
genos.co
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
11-50

Section iconFunding & Financials

  • $1M

    Genos (acquired by NantOmics)'s revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $1M

    Genos (acquired by NantOmics)'s revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.